Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05298254 · ClinicalTrials.gov registry record · Phase 1
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 505
- Enrollment target
NCT05298254 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 505 participants.
The verdict
NCT05298254, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 505 participants
- Enrollment target
Study Summary
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI). The study will be conducted in 2 parts: Part I assessing different formulations of the Herpes Simplex Virus-targeted immunotherapy (HSVTI) in healthy participants aged 18-40 years; Part II assessing the 2 formulations of the HSVTI in participants aged 18-60 years with recurrent genital herpes.
Interventions
- BIOLOGICAL Non-adjuvanted HSV formulation 1
- BIOLOGICAL Non-adjuvanted HSV formulation 2
- BIOLOGICAL Non-adjuvanted HSV formulation 3
- BIOLOGICAL HSV formulation 1 with adjuvant 1
- BIOLOGICAL HSV formulation 2 with adjuvant 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2025-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05298254
The ClinicalTrials.gov registry entry for NCT05298254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Non-adjuvanted HSV formulation 1 is the first listed.
NCT05298254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05298254 about?
NCT05298254 is a clinical study titled "A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes". The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI). The study will be conducted in 2 parts: Part I assessing different formulations of the Herpes Si...
What is the current status of trial NCT05298254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 505 participants. The study started on 2022-03-07. Estimated completion is 2025-06-12.
What interventions are being tested in trial NCT05298254?
The interventions under investigation include: Non-adjuvanted HSV formulation 1 (BIOLOGICAL), Non-adjuvanted HSV formulation 2 (BIOLOGICAL), Non-adjuvanted HSV formulation 3 (BIOLOGICAL), HSV formulation 1 with adjuvant 1 (BIOLOGICAL), HSV formulation 2 with adjuvant 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05298254?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.